News

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine Bilthoven, the Netherlands, 12 September 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable…

• Additional pre-clinical data of Avacc 10® indicate reduction in upper respiratory tract viral load and cross neutralization of variants of concern
• Avacc 10® toxicology data support the start of a phase I clinical trial in Q4 2022

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the…

• Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development
• ALS vaccine is targeting the most common genetic ALS variant
• 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors Bilthoven, the Netherlands, 5 July 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced…

• Publication annual report 2021
• Appointment of a Chief Business Officer
• Appointment of a Director vaccine process development
• Chief Financial Officer joins the Board of Directors

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive…

• Avacc 3 has significant advantages over existing whooping cough vaccines
• Second major OMV platform licensing agreement with pharmaceutical company
• Over 24 million cases of whooping cough per year world-wide

Intravacc announces the publication of a GMP process for a semi-synthetic Shigella glycoconjugate vaccine candidate from the Institut Pasteur Bilthoven, the Netherlands, and Paris, France, 22 March 2022 – Intravacc, a world leader in translational research and development of preventive…

• Data published in the prestigious journal ACS Central Science of the American Chemical Society
• Preclinical and clinical batches complying with ICH guidelines and WHO recommendations
• Phase I clinical study showed vaccine was safe and well tolerated
• Phase II clinical studies ongoing in endemic countries

Leiden University Medical Center and Intravacc to start clinical trial with new intranasal corona vaccine Bilthoven, the Netherlands, 5 January 2022 – Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today…

• Nasal spray vaccine based on soluble nano-spheres with synthetic corona proteins
• No use of mRNA or vector technology
• Better and direct immunization of mucosa against multiple corona viruses
• Intravacc focuses on preclinical and process development research and GMP vaccine production
• Financing of clinical trial study made possible in part by Dutch governmental body Top Consortium for Knowledge and Innovation (TKI)

Intravacc launches hybrid business model to drive innovation and growth Bilthoven, the Netherlands, 16 September 2021 – Intravacc, a global leader in translational research and the development of vaccines against infectious diseases and therapeutic vaccines, today launches its new hybrid…

• Hybrid model: CDMO services and development of a proprietary vaccine pipeline
• Intravacc will also put emphasis on the therapeutic vaccine market
• Intravacc’s proprietary vaccine portfolio will mainly focus on intranasal administration
• Intravacc launches promotional campaign, supporting the funding of a phase I clinical trial with the Avacc 10 nasal spray vaccine

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China Bilthoven, the Netherlands, 20 July 2021 – Intravacc, a world leader in translational research and development of vaccines for infectious diseases and therapeutics, today announced that the…

• Sabin-IPV polio vaccine developed by Intravacc contributes to the eradication of polio
• Sinovac’s polio vaccine (sIPV) receives market authorization from the NMPA in China
• Intravacc’s cell technology also used for the development of Sinovac’s Covid-19 vaccine that was introduced on the market recently and is currently under rolling review by EMA

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme…

• Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
• Two conventional vaccines based on Intravacc's OMV platform and VERO cell platform

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine Bilthoven, the Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive pre-clinical results…

• Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2
• Intranasal vaccine administration has significant advantages over injectables
• OMV technology is a powerful vaccine platform for future pandemics

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer Bilthoven, the Netherlands, 24 March 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the appointment of Nathalie Laarakker as Chief Financial Officer and member…

Intravacc announces formation of Scientific Advisory Board Bilthoven, the Netherlands, 23 February 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the formation of a Scientific Advisory Board (“SAB”), chaired by Intravacc’s Chief Scientific…

Intravacc neemt moderne pilot productiefaciliteit in gebruik en start concept-design van multifunctionele vaccinfabriek Bilthoven, the Netherlands, 19 februari 2021 – Intravacc, wereldwijd vooraanstaand op het gebied van translationeel onderzoek naar en de ontwikkeling van vaccins, maakt bekend dat haar nieuwe moderne…

• Pilotfabriek geschikt voor productie van vaccins in klinische fase I & II onderzoek
• Consortium werkt plan uit voor nieuwe multifunctionele vaccinfabriek
• Uitgebreide omgevingsvergunningen maken snelle realisatie mogelijk

Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement New state-of-the-art pilot vaccine production facility ready for use   Bilthoven, the Netherlands, 19 February 2021 – Intravacc, a world leader in translational research and development of…

• New pilot plant for production of vaccine candidates in clinical phase I & II research
• Consortium starts concept design for new multifunctional vaccine factory that can produce enough vaccines for the Netherlands during pandemic
• Extensive environmental permits already in place will enable rapid construction

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification Bilthoven, the Netherlands, 21 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV)…

• sIPV development is part of Intravacc’s contribution to the eradication of polio
• LG Chem is the first to receive WHO prequalification for the sIPV vaccine
• LG Chem signed an $80 million contract with UNICEF to supply polio vaccine starting early 2021

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio Bilthoven, the Netherlands, 19 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent…

• Potentially the first preventive vaccine for coxsackievirus B, a risk factor associated with type 1 diabetes and celiac disease
• First dosing of PRV-101 in the PROVENT Phase I clinical trial started in January 2021

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics,  a technology leader in enabling…

• First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2
• Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology

Intravacc appoints three Supervisory Board members Bilthoven, the Netherlands, 4 January 2021 – Intravacc, a world leader in translational research and development of vaccines, announces the appointment of three members in its Supervisory Board. As of January 1, 2021, Intravacc…

• Appointment of Nico Oudendijk (Chair), Bruno Bruins and Karin Dorrepaal
• Intravacc has become public shareholding company as per January 1, 2021

Dutch vaccine developer Intravacc becomes public shareholding company effective 1st January 2021 Bilthoven, The Netherlands, 22 December 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing infectious diseases vaccines,…

• Dutch State will become sole shareholder
• Jan Groen will continue as Chief Executive Officer

Intravacc publishes positive phase I Shigella conjugate vaccine data Bilthoven, The Netherlands, 16 November 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced…

• High medical need for Shigella vaccine
• Over 250 million infections worldwide annually
• Vaccine was well tolerated and induced a significant increase in functional antibodies
• Data published in prestigious journal The Lancet Infectious Diseases

Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer Bilthoven, The Netherlands, 5 November 2020 – Intravacc, a global leading contract development and manufacturing organization of viral and bacterial vaccines, today announced the appointment of Prof. Dr. Virgil Schijns,…

Intravacc 2.0 Bilthoven, The Netherlands, 5 October 2020 – After many months of hard work and dedication by our team at Intravacc together with our branding and website agencies, we are pleased to announce the launch of Intravacc 2.0! Our…

• New website and branding
• Matches Intravacc’s aspiration to become a leading vaccine CDMO
• We welcome your feedback on our new website

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine Bilthoven, The Netherlands, 8 September, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract…

• Growing concerns about global spread of this respiratory enterovirus
• Vaccine to protect children from Acute Flaccid Myelitis
• Development of inactivated EV D68 vaccine, through to Phase I clinical testing

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx,…

• Gonorrhea is the second most common bacterial infectious disease worldwide
• Vaccine based on IL12 in combination with intravacc’s gonorrhea OMV targeting mucosal immunization
• Induce an adaptive immune response for long term protection against the gonorrhea bacteria
• Mucosal vaccine platforms offer a broader perspective also for respiratory virus vaccines, such as Covid-19 and influenza

Intravacc’s candidate RSV vaccine demonstrates safety in phase I trial Bilthoven, The Netherlands, 18 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine,…

• High unmet need for effective pediatric RSV vaccine
• Continued frequent hospitalization of infected infants and risk to elderly
• Partner orientation for further development of this RSV candidate vaccine

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine BILTHOVEN, Netherlands and BASEL, Switzerland, 29 July, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, and Celonic Group, a premium biopharmaceutical…

• Combining Intravacc’s OMV-delivery platform with Covid-19 Spike proteins
• Preclinical studies to start shortly for candidate selection and inhouse pilot scale GMP production

Intravacc and Leiden University developed an animal replacement method for vaccines Bilthoven, The Netherlands, 23 July 2020 – Dutch, Bilthoven based, Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication of…

• Need for alternatives to animal testing in quality control of vaccines
• Inactivation of vaccines can be traced without using laboratory animals
• Findings published in medical journal Scientific Reports

Intravacc to in-license CimCure’s iBoost technology, expanding its vaccine platform portfolio Bilthoven, The Netherlands, 1 July 2020 – Bilthoven, The Netherlands based Intravacc, a worldwide leading translational research and development vaccine organization with an extensive track record in developing viral…

• iBoost technology well suited for developing cancer vaccines
• Joint development of Covid-19 vaccine using iBoost

Intranasal immunization with Intravacc’s experimental whooping cough vaccine confers broad protection Bilthoven, The Netherlands, 22 June 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines,…

• Need for improved whooping cough vaccines
• Outer membrane vesicles from Bordetella pertussis bacteria are potent immunogens
• Intranasal immunization shows both excellent systemic and immune responses
• Needle free immunization possible
• Data published in medical journal Scientific Reports

Intravacc and Versatope sign research service agreement to develop universal influenza vaccine based on OMV technology Bilthoven, The Netherlands, Lowell, Mass., USA, June 8 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive…

• Influenza vaccines were overall only 29% effective during the 2018–2019 influenza season
• High medical costs drive the need for finding a more universal influenza vaccine
• Intravacc’s OMV technology platform well suited to support the development of new pandemic response vaccines

Intravacc partners with Wageningen Bioveterinary Research and Utrecht University to develop an intranasal COVID-19 vaccine Bilthoven, Lelystad and Utrecht, The Netherlands, 4 June 2020 – Intravacc, one of the world’s leading translational research and development vaccine institutes, with an extensive…

• Development through a newly established public private partnership
• Vaccine consists of a Newcastle disease virus (NDV) vector, expressing the immunogenic spike (S) protein of SARS-CoV-2
• Intravacc to develop a scalable vaccine production process, using its FDA-approved Vero cell platform, in preparation of GMP productions

Intravacc to develop emergency and conventional COVID-19 vaccines Bilthoven, The Netherlands – 08.00 CET, May 14, 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines,…

• Vaccine concepts based on Intravacc’s platform technologies, proven safe in humans
• Emergency vaccine designed to activate cytotoxic T-cell responses
• Data are published in peer reviewed journal Vaccine

Intravacc appoints Dr Jan Groen as CEO Bilthoven, The Netherlands – 07.00 CRT, April 3, 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record developing viral and bacterial vaccines from discovery…